Parkinson's disease (PD), a neurodegenerative disorder with progressive characteristics, is primarily associated with dopaminergic neuron loss within the substantia nigra. This article provides an in-depth understanding of the progression and management of PD.
The progression of PD is typically gradual, often beginning with a barely noticeable tremor in one hand. As the disease progresses, symptoms become more noticeable and debilitating. Motor symptoms such as bradykinesia, rigidity, and postural instability may emerge. Non-motor symptoms such as autonomic dysfunction, cognitive impairment, and psychiatric symptoms can also occur. The Hoehn and Yahr scale is commonly used to describe the progression of PD, ranging from stage 1 (mild symptoms) to stage 5 (severe disability).
Diagnosis is primarily clinical, based on the presence of cardinal motor symptoms and response to dopaminergic therapy. Neuroimaging techniques, such as DaTscan, can be used to support the diagnosis in uncertain cases.
Management of PD is multifaceted and typically includes pharmacological treatment, physical therapy, and surgical interventions. Pharmacological treatment primarily involves dopamine replacement therapy, such as Levodopa. Non-pharmacological interventions include regular physical exercise and occupational therapy. Deep brain stimulation is a surgical option for patients with advanced disease or those who do not respond adequately to medication.
Research into neuroprotective therapies, such as MAO-B inhibitors, is ongoing. These therapies aim to slow disease progression. Gene therapy and stem cell therapy are promising future directions.
Understanding the progression and management of PD is crucial for healthcare professionals. While current treatments aim to manage symptoms and improve quality of life, emerging therapies may offer hope for altering the course of this debilitating disease.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation